Keyphrases
Phase II Study
100%
Recurring
100%
Carboplatin
100%
Ovarian Cancer Patients
100%
Pegylated Liposomal Doxorubicin
100%
Platinum Sensitivity
33%
Carboplatin-paclitaxel
33%
Disease Stabilization
33%
Chemotherapy
16%
Median Time
16%
Adverse Effects
16%
Response Rate
16%
Phase II Trial
16%
Median Overall Survival
16%
Thrombocytopenia
16%
Time to Progression
16%
Neutropenia
16%
Initial Treatment
16%
Efficacy Analysis
16%
Constipation
16%
Platinum-based Chemotherapy
16%
Platinum-resistant Ovarian Cancer
16%
Objective Response Rate
16%
6-cycles
16%
Optimal Therapy
16%
Carbohydrate Antigen 125 (CA125)
16%
Early Relapse
16%
Pharmacology, Toxicology and Pharmaceutical Science
Ovary Cancer
100%
Carboplatin
100%
Doxorubicin
100%
Disease
28%
Chemotherapy
28%
Paclitaxel
28%
Adverse Event
14%
Overall Survival
14%
Phase II Trials
14%
Thrombocytopenia
14%
Neutropenia
14%
Constipation
14%
Medicine and Dentistry
Platinum-Sensitive Ovarian Cancer
14%